Targeted Cell Therapies
Targeted Cell Therapies (TCT) is an early-stage Massachusetts-based biopharmaceutical company that is using its powerful technology platform for the development of biotherapeutics for a broad range of human diseases.
TCT’s technology permits the oral delivery of large molecules, avoiding the usual need for injection. The Company’s approach uses yeast cell wall particles (YCWP) containing nanoplexed nucleic acid (DNA or RNA) payloads that encode for therapeutic molecules. Following oral administration, the YCWPs and their payload are rapidly taken up by macrophages in the small intestine. As the macrophages migrate to sites of inflammation or pathology, the YCWP payloads are processed by cellular machinery and produce active therapeutics.
TCT’s lead compound is for Gaucher Disease, the most common lysosomal storage disorder. TCT believes that its orally administered therapy will be more efficacious and safer than the current standard of care. Animal studies have already demonstrated the effectiveness of the approach. Later targets include low bone density conditions and inflammatory disorders.